The PARP inhibitor Olaparib was observed to induce both phosphorylation and stabilization of p53 in a DNA-PK-dependent manner in mantle cell lymphoma cells lacking ATM and promote the expression of p53-responsive factors responsible for regulating cell-cycle checkpoints. The gene discussed is TP53; the disease is mantle cell lymphoma.